Hopp til hovedinnhold

Systemisk sklerose

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Er en multiorgan, autoimmun sykdom karakterisert ved avleiring og akkumulering av store mengder kollagen og ekstracellulær-matriks molekyler.
Forekomst:
Sjelden.
Symptomer:
Symmetrisk sklerose i huden og skader på spiserør, lunger, hjerte og nyrer m.m.
Funn:
Særlig hudforandringer, men etter hvert affeksjon av indre organer hos en stor andel. 
Diagnostikk:
Blodprøver viser økt CRP, trombocytopeni, hypergammaglobulinemi, ev. økt kreatinin, ANA-positiv, histologiske forandringer i hudbiopsier, bildediagnostikk kan vise ev. andre organskader.
Behandling:
Spesialistbehandling. Individuell vurdering avhengig av symptomer og hvilke organer som er involvert. En lang rekke medikamenter er aktuelle, men ingen har helbredende effekt.
  1. Kowal-Bielecka O, Fransen J, Avouac J EUSTAR Coauthors, et alUpdate of EULAR recommendations for the treatment of systemic sclerosisAnnals of the Rheumatic Diseases 2017;76:1327-1339. ard.bmj.com  
  2. Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Seminar. Lancet 2022. pmid:36442487 PubMed  
  3. Schwartz RA. Systemic sclerosis. Medscape, last updated Mar 13, 2018. emedicine.medscape.com  
  4. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223-35. pmid:17692364 PubMed  
  5. Gran JT, Molberg Ø, Midtvedt Ø. Patofysiologiske aspekter ved systemisk sklerose. Tidsskr Nor Lægeforen 2005; 125: 2622-3. PubMed  
  6. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10. PubMed  
  7. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 06, 2017. UpToDate  
  8. Varga J. Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 05, 2017. UpToDate  
  9. Gran JT, Midtvedt Ø. Iskemiske sår ved systemisk bindevevssykdom. Tidsskr Nor Lægeforen 2006; 126: 3089-92. PubMed  
  10. Kuwana M. Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting. J Nippon Med Sch 2017; 84(2): 56-63. pmid:28502960 PubMed  
  11. Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG). Arthritis Care Res (Hoboken). 2012; 64(9):1405-14. PubMed  
  12. Derrett-Smith EC, Nihtyanova SI, Harvey J, et al. Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) 2013; 52:1824. PubMed  
  13. Denton CP. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Oct 10, 2014. UpToDate  
  14. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015 Jun; 74:1188. Doi: 10.1136/annrheumdis-2013-204522 DOI  
  15. Kuzumi A, Ebata S, Fukasawa T, et al. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels. JAMA Dermatol 2023; 159: 374-383. pmid:36790794 PubMed  
  16. Tashkin DP, Roth MD, Clements PJ et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet respir Med 2016; 4: 708. doi:27469583
  17. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 PMID: 31112379 PubMed  
  18. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun 25;311(24):2490-8. PubMed  
  19. Sullivan KM., Goldmuntz EA., Keyes-Elstein L. et al.. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378: 35-47. pmid:29298160 PubMed  
  20. Onishi A, Sugiyama D, Kumagai S, et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013 Jul;65(7):1913-21. doi: 10.1002/art.37969. DOI  
  21. Tennøe AH, Murbræch K, Andreassen JC, et al. Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. Journal of the American College of Cardiology, volume 72, issue 15, October 2018.
  22. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809. PubMed  
  • Ingard Løge, spesialist i allmennmedisin, redaktør NEL
  • Morten Dalaker, avtalespesialist i hudsykdommer, Trondheim Hudlegesenter, Carl Johans gt 3, 7010 Trondheim

Tidligere fagmedarbeidere

  • Sylvi Torvund, spesialist i allmennmedisin, Nidarvold legesenter, Trondheim
  • Mette Mogensen, overlæge, klinisk lektor, ph.d., Dermato-Venerologisk afd. D, Bispebjerg og Frederiksberg Hospital